Luminex Posts 12 Percent Q2 Revenue Growth; Stock Sinks | GenomeWeb

NEW YORK (GenomeWeb News) – Luminex reported after the close of the market Monday that its second-quarter revenues grew 12 percent year over year, driven by a 24 percent spike in its assay revenue.

The Austin, Texas-based molecular diagnostics firm reported total revenues of $54.3 million for the three months ended June 30, compared to $48.3 million for the second quarter of 2012. It inched past analysts' consensus estimate for revenues of $54.2 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.